Andere Sprachen Torii Pharmaceutical Co., Ltd.

Aktien

887536

JP3635800000

4551

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 24.05.2024			% 5 Tage	% 1. Jan.
3.740 ^JPY	-1,19 %		-3,86 %	+5,20 %

15.05.	Verrica Pharmaceuticals ändert Lizenzvereinbarung mit Torii Pharmaceutical für Phase-3-Studie von Ycanth	MT
15.05.	Verrica Pharmaceuticals Inc. kündigt Änderung der Kooperations- und Lizenzvereinbarung mit Torii Pharmaceutical Co. Ltd. zur Finanzierung einer globalen klinischen Phase-3-Studie zur Untersuchung von Ycanth zur Behandlung von gewöhnlichen Warzen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	15.05.
Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	15.05.
LIM Advisors Partially Withdraws Shareholder Proposal	13.02.
Torii Pharmaceuticals Opposes Shareholder Proposal	09.02.
Torii Pharmaceutical - Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	18.12.
Verrica Pharmaceuticals Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208	18.12.
Verrica Pharmaceuticals' Partner Reports Positive Data From Phase 3 Trial of Skin Infection Treatment	15.12.
Torii Pharmaceutical : Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	15.12.
Torii Pharmaceutical Co., Ltd. Announces Positive Top-Line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan	15.12.
Torii Pharmaceutical : Signing of an Agreement for the Exclusive Development and Commercialization of GRAZAX®,an Allergen Immunotherapy (Sublingual Immunotherapy) Drug for Grass Pollinosis in Japan	13.12.
ALK Abello Adds Grass Pollen Allergy Drug to Torii License Deal in Japan	12.12.
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	12.12.
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise	30.11.
Torii Pharmaceutical : Financial Results for the First Nine Months of Fiscal Year Ending December 2023	31.10.23
Torii Pharmaceutical - JT Files New Drug Application of JTE-061 Cream, Aryl hydrocarbon Receptor agonist, for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	18.09.23
Torii Pharmaceutical : JT Files New Drug Application of JTE-061 Cream,Aryl hydrocarbon Receptor (AhR) agonist,for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	15.09.23
Torii Pharmaceutical : Financial Results for the First Three Months of Fiscal Year Ending December 2023	28.04.23
Torii Pharmaceutical Announces Voting Results	30.03.23
Torii Pharmaceutical : Views on Report from ISS, a Proxy Advisory Firm, On Proposals for ’s General Meeting of Shareholders	16.03.23
Torii Pharmaceutical : Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal	17.02.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Torii Pharmaceutical Co., Ltd.

Aktien

887536

JP3635800000

4551

Andere Sprachen

Filter